Financiere de Tubize SA banner

Financiere de Tubize SA
XBRU:TUB

Watchlist Manager
Financiere de Tubize SA Logo
Financiere de Tubize SA
XBRU:TUB
Watchlist
Price: 195.7 EUR 2.19% Market Closed
Market Cap: €8.7B

EV/FCFF

-2584.5
Current
11%
Cheaper
vs 3-y average of -2901.7

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-2584.5
=
Enterprise Value
€9.1B
/
Free Cash Flow to Firm
€-3.4m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-2584.5
=
Enterprise Value
€9.1B
/
Free Cash Flow to Firm
€-3.4m

Valuation Scenarios

Financiere de Tubize SA is trading above its industry average

If EV/FCFF returns to its Industry Average (43.3), the stock would be worth €-3.28 (102% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-102%
Maximum Upside
No Upside Scenarios
Average Downside
101%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple -2 584.5 €195.7
0%
Industry Average 43.3 €-3.28
-102%
Country Average 21.8 €-1.65
-101%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
BE
Financiere de Tubize SA
XBRU:TUB
8.7B EUR -2 584.5 93.4
US
Eli Lilly and Co
NYSE:LLY
883B USD 153.6 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 29.4 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 35.4 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 24.5 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 19.6 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 44.6 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 22 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 12 17.3
P/E Multiple
Earnings Growth PEG
BE
Financiere de Tubize SA
XBRU:TUB
Average P/E: 29.5
93.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Lower than 100% of companies in Belgium
Percentile
0th
Based on 325 companies
0th percentile
-2 584.5
Low
2.1 — 13.2
Typical Range
13.2 — 29.4
High
29.4 —
Distribution Statistics
Belgium
Min 2.1
30th Percentile 13.2
Median 21.8
70th Percentile 29.4
Max 1 136.6

Financiere de Tubize SA
Glance View

Market Cap
8.7B EUR
Industry
Pharmaceuticals

Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.

TUB Intrinsic Value
22.07 EUR
Overvaluation 89%
Intrinsic Value
Price €195.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett